The aml Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the aml Hub cannot guarantee the accuracy of translated content. The aml and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The AML Hub is an independent medical education platform, sponsored by Astellas, Daiichi Sankyo, Johnson & Johnson, Kura Oncology and Syndax, and has been supported through educational grants from Bristol Myers Squibb and the Hippocrate Conference Institute, an association of the Servier Group. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View aml content recommended for you
Visual Abstract | Venetoclax plus azacitidine for patients with IDH1/2 mutated AML who are ineligible for intensive chemotherapy
The AML Hub is delighted to present a visual abstract representing key data pooled from the phase III Viale-a trial (NCT02993523) and a phase Ib trial (NCT02203773) investigating the efficacy and safety of venetoclax plus azacitidine and azacitidine monotherapy in treatment-naïve patients with acute myeloid leukemia (AML) who are ineligible for intensive chemotherapy. This analysis will focus on isocitrate dehydrogenase (IDH) 1/2 mutational status; however, an overview of the Viale-a trial has been previously reported by the AML Hub, as well as articles on MRD response and TP53 mutational status.
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
Your opinion matters
Approximately what proportion of your patients with FLT3-mutations also have NPM1 and DNMT3A co-mutations?
